

Gabriela Cesarman Cesarman-Maus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6413626/publications.pdf>

Version: 2024-02-01

20
papers

1,246
citations

840119

11
h-index

713013

21
g-index

21
all docs

21
docs citations

21
times ranked

1888
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mechanisms of fibrinolysis. <i>British Journal of Haematology</i> , 2005, 129, 307-321.	1.2	570
2	A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. <i>Lancet Haematology</i> , 2018, 5, e289-e298.	2.2	219
3	Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. <i>Blood</i> , 2006, 107, 4375-4382.	0.6	159
4	The Annexin A2/S100A10 System in Health and Disease: Emerging Paradigms. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-13.	3.0	85
5	Thrombosis in multiple myeloma (MM). <i>Hematology</i> , 2012, 17, s177-s180.	0.7	40
6	Autoantibodies Against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis. <i>Stroke</i> , 2011, 42, 501-503.	1.0	32
7	Oncolytic Viruses for Canine Cancer Treatment. <i>Cancers</i> , 2018, 10, 404.	1.7	31
8	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520.	1.0	27
9	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	1.9	17
10	Newcastle Disease Virus: Potential Therapeutic Application for Human and Canine Lymphoma. <i>Viruses</i> , 2016, 8, 3.	1.5	15
11	Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. <i>Thrombosis Research</i> , 2014, 133, 606-609.	0.8	14
12	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 532-535.	1.9	7
13	Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210829.	0.7	7
14	The Consular Program for Mexican Communities Abroad: A Source of Outreach for Health Workers. <i>Journal of Transcultural Nursing</i> , 2003, 14, 272-275.	0.6	4
15	Annexin checks in - Response to Waisman. <i>British Journal of Haematology</i> , 2005, 131, 554-556.	1.2	4
16	Personalizing the Use of Circulating Microparticle-Associated Tissue Factor As a Biomarker for Recurrent Thrombosis in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2217-2218.	0.8	3
17	Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. <i>Internal Medicine Journal</i> , 2020, 50, 366-370.	0.5	3
18	Apixaban in low-weight patients with cancer-associated thrombosis: A cross sectional study of drug levels. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 421-425.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Venous Thromboembolism in Patients with Cancer Receiving Specialist Palliative Care. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962210811.	0.7	2
20	Anticoagulant Proteins in a Population of Mexican Mestizo Donors. <i>Annals of Vascular Surgery</i> , 2015, 29, 222-226.	0.4	1